FDA offers guidance on labeling mutation risks of ingredients; Accuratus gets CMC operation;

> The FDA has issued guidance on the need for drugmakers to assess and label the risks of impurities in drugs to create DNA mutations that might lead to cancer. Guidance

> Accuratus Lab Services has acquired Array BioPharma's chemistry, manufacturing and controls (CMC) operation to expand its its CDMO services. Report

> An FDA advisory committee next month will evaluate post marketing studies of the use and abuse of the new abuse deterrent formulation of Oxycontin ER. Report